Boston Scientific Files 8-K Report
Ticker: BSX · Form: 8-K · Filed: 2024-04-04T00:00:00.000Z
Sentiment: neutral
Topics: corporate-filing, 8-k
Related Tickers: BSX
TL;DR
BSX filed a standard 8-K, no major news.
AI Summary
On April 3, 2024, Boston Scientific Corporation (BSX) filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or new material agreements, but rather standard corporate reporting information.
Why It Matters
This filing indicates routine corporate activity and does not represent a significant event or change for investors.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- Boston Scientific Corporation (company) — Registrant
- BSX (company) — Ticker Symbol
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report an 'Other Event' as of April 3, 2024, which is a standard corporate disclosure.
When was this 8-K report filed?
This 8-K report was filed on April 4, 2024.
What is the principal executive office address for Boston Scientific Corporation?
The address of the principal executive offices is 300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234.
What is the state of incorporation for Boston Scientific Corporation?
Boston Scientific Corporation is incorporated in Delaware.
Does this filing announce any new financial results or material agreements?
No, this filing is categorized under 'Other Events' and does not appear to announce new financial results or material agreements based on the provided text.
From the Filing
0000885725-24-000037.txt : 20240404 0000885725-24-000037.hdr.sgml : 20240404 20240404071911 ACCESSION NUMBER: 0000885725-24-000037 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240403 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240404 DATE AS OF CHANGE: 20240404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 24821613 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20240403.htm 8-K bsx-20240403 0000885725 false 0000885725 2024-04-03 2024-04-03 0000885725 us-gaap:CommonStockMember 2024-04-03 2024-04-03 0000885725 bsx:SeniorNotedue2027Member 2024-04-03 2024-04-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): April 3, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ ITEM 8.01    OTHER EVENTS As previously disclosed, on January 8, 2024, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company